Ciliatech, an ophthalmic medical technology company developing new implants for the ongoing treatment of glaucoma, has launched a new design of CID (Cilioscleral Interpositioning Device) following additional patent applications that strengthen its intellectual property rights (IP).
CID is a unique glaucoma surgical device used in cilioscleral technology that lowers intraocular pressure (IOP) while preserving the anterior chamber of the eye, preventing serious medical complications, especially endothelial cell loss (ECL) or filtration blisters. Cilioscleral technology is also unique in its ability to treat the two main types of glaucoma: open-angle or closed-angle (narrow-angle).
The new patent primarily protects modifications to the shape and geometry of the CID to further improve its performance and safety. Currently in clinical trials, this second-generation CID makes cilioscleral technology less invasive and traumatic to the eye. The conjunctiva is better protected and the incision area is smaller.
Philippe Sourdille, co-founder of Ciliatech and inventor of CID, said: “We are very pleased with the performance of the second generation CID. We redesigned it to provide an unparalleled safety profile and improved IOP reduction and maintenance over time without medication. The new CID improves on the very positive results already achieved with the first generation devices in all aspects: performance, safety, surgical technique and postoperative medication. This demonstrates the progress Ciliatech has made in understanding the key underlying mechanisms that monitor aqueous humor circulation. We are identifying important parameters to leverage clinical outcomes. This is the CID design for which we will apply for CE marking and bring it to market in 2025.”
Ciliatech has secured a patent for modifying the shape of the CID implant to improve moisture collection in the anterior chamber and circulation into the drainage channels. The overall size has been slightly modified to allow for smaller incisions and reduce the invasiveness of the procedure.
Preliminary results from a 12-month clinical study (SAFARI III) in 57 patients using the new design showed that this second-generation CID achieved better IOP control of 13.9 mmHg compared to 15.1 mmHg in previous studies (SAFARI I and II). It appears that they tend to provide ) Uses the 1st generation model. Ciliatech says this is especially important when post-operative IOP is already in the low teens. SAFARI III 12-month results reported that more than 85% of patients were drug-naive.
For surgeons, this new model allows cilioscleral procedures to be performed faster (less than 15 minutes) and easier, further reducing the learning curve. CID can be used similarly to the MIGS (Minimally Invasive Glaucoma Surgery) device in patients with open-angle glaucoma. Unlike MIGS, it can be used to treat primary angle closure glaucoma, in which patients have a two-fold higher risk of vision loss over their lifetime without the need for lens removal.
“This second-generation CID may also benefit more advanced glaucoma cases through stronger IOP reduction, helping more patients postpone the need for traditional incision approaches,” said Olivier Benoit, CEO of Ciliatech. He said.
Ciliatech's CID is a non-absorbable implant that stays in place for the patient's entire life. It is a monolith of 26% hydrophilic acrylic, a raw material widely used in the manufacture of intraocular lenses, ensuring long-term biocompatibility. The device consists of a specially designed 6 mm large, 3.5 mm wide, 500 μm thick plate. The leading edge contains several contact points to adapt to natural changes in iris diameter between patients.